Abstract Title
Tackling highly pathogenic avian influenza using vaccination: sorting out among novel vaccine technology options
Abstract
Highly pathogenic avian influenza (HPAI) is a deadly and devastating disease for poultry. The recent emergence and unprecedented widespread of 2.3.4.4b clade of H5Nx HPAI virus brought new concerns since this strain is also capable of infecting a wide variety of wild birds and mammals. Zoonotic cases are reported from time to time. Vaccination of poultry is nowadays regarded as a useful tool, on top of biosecurity and monitoring strengthening. However, vaccines should comply with several key criteria of efficacy, which include protection against mortality and morbidity against the current clade, a given rate of reduction of shedding, the need for optimum flock coverage, and the easiness of monitoring through DIVA strategy (differentiating infected from vaccinated animals).
Most of the traditional inactivated, water-in oil vaccines do not comply with some of the above criteria.
On the other hand, novel technologies like vector HVT, and self-amplifying RNA vaccines do comply with them. Both are currently used in the field in millions of commercial poultry in various parts of the world.
The present paper aims at displaying their assets, as well as their limitations for a better understanding and respective use. It opens new perspectives for the long-term control of HPAI, which may include its eradication from a given area.
Most of the traditional inactivated, water-in oil vaccines do not comply with some of the above criteria.
On the other hand, novel technologies like vector HVT, and self-amplifying RNA vaccines do comply with them. Both are currently used in the field in millions of commercial poultry in various parts of the world.
The present paper aims at displaying their assets, as well as their limitations for a better understanding and respective use. It opens new perspectives for the long-term control of HPAI, which may include its eradication from a given area.
Co-Author(s)
C. Cazaban1, T. Tatar-Kis2, Z. Gyuro2, K. Kamrud1, I. Kiss2, E. Rausch2, J. Elattrache1, G. Dauphin1, J. Lee1, M.S. Sandikli1, S. Comte1
1: Ceva Animal Health, Libourne, France; 2: Ceva Animal Health, Budapest, Hungary.
Abstract Category
Diagnostics, vaccination, or other mitigation strategies for poultry and wildlife